Prismmulti-framework research
Prism

See every stock through 15+ investor lenses. Research, decide, document — without leaving the page.

For research and education only — not investment advice.

Research
  • Browse
  • Screener
  • Markets
  • Superinvestors
  • Insider tracker
Tools
  • Backtest
  • Calculators
  • Compare
  • Copilot
Workspace
  • Portfolio
  • Watchlist
  • Alerts
  • Weekly digest
  • Learn
© 2026 Prism Finance. All data illustrative.GlossaryContact
  • Browse
  • Screener
  • Disagree
  • Portfolio
PFE logo

PFE

Pfizer Inc.
HealthcareDrug Manufacturers - GeneralIncome
$26.05 · 15min delay
β 0.30

A steady large-cap income stock trading at a premium valuation.

Download report

52-wk low $21.9752-wk high $28.75

Mkt Cap

$148.44B

P/E

—

PEG

13.77

P/B

1.71

Dividend

6.66%

ROE

8.3%

About the business

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Who would buy PFE?

Consensus 13/100 · Mixed · Investors are split.

0 8 7

Endorses

· 2 frameworks
  • Fama / French· Pure Value Factor67/100

    FCF Yield > 5% 8.3% clears "> 5.0%".

  • Dividend Growth School· Dividend Income63/100

    Dividend Yield > 2% 6.7% clears "> 2.0%".

Rejects

· 3 frameworks
  • Peter Lynch
Insider activity · Routine

Activity is dominated by option exercises

Strength 15/100

Recent filings are almost entirely option exercises and awards. These are compensation-driven and do not represent an active view on the stock.

In Prism's context

Prism treats insider activity here as a low-weight input. It neither strengthens nor materially weakens the framework read (Fails criteria).

InsiderRoleTypeDateSharesAvg priceValueOwn
DAMICO JENNIFER B.OfficerAward / grantMar 3, 202621,719$0.00$0Direct
BOURLA ALBERTChief Executive OfficerOption exerciseFeb 25, 2026491,626$33.82$16.63MDirect
DAMICO JENNIFER B.OfficerOption exerciseFeb 25, 202617,558$33.82$594KDirect
SAHNI PAYALOfficerOption exerciseFeb 25, 202656,888$33.82$1.92MDirect
MCDERMOTT MICHAELOfficerOption exerciseFeb 25, 202637,925$33.82$1.28MDirect
BOSHOFF CHRISTOFFELOfficerAward / grantFeb 25, 202613,383$0.00$0Direct
FONSECA LIDIA PH.D.OfficerOption exerciseFeb 25, 202656,888$33.82$1.92MDirect
LANKLER DOUGLAS MOfficerOption exerciseFeb 25, 2026122,907$33.82$4.16MDirect

Insider activity from Yahoo Finance (quoteSummary: insiderTransactions + netSharePurchaseActivity). Cached 6 hours. · Insiders hold 0.1% of shares outstanding.

Net 6M: +0 sh

Price history

—
Loading…

Drag across the chart to select a custom period — all analysis below refocuses to that window.

Premium view

AI summaries

Members get a plain-English 'what matters now' brief plus an explanation of why the price is moving, grounded in Prism's framework scores.

Premium view

Full framework decision report

See how Lynch, Buffett, Graham, Greenblatt, Fisher and more each score this stock — with every rule, threshold, and reason exposed.

Premium view

Peer comparison + AI read-through

See how this stock stacks up against its closest peers on valuation, growth, and returns — with a written peer summary.

What would PFE do to your portfolio?

Add Pfizer Inc. at a hypothetical weight and Prism recalculates your whole book:

Risk metrics

Sharpe, Sortino, volatility, max drawdown, beta — before and after.

Sector concentration

How much this shifts your top sector weight and overall diversification.

Archetype tilt

Whether this leans your book more toward Quality, Value, Growth, Deep Value, Income, or Momentum.

PFE is currently tagged:IncomeFails criteria (13/100)

Portfolio analytics are part of the member experience.

Sign in to run this simulation
Probabilistic recommendation· rec-v1.0.0-2026-04

Pfizer Inc. · PFE

PFE: 53% estimated probability of outperforming over the next 12M window. 1 of 6 signal families positive (medium confidence). Strongest support: Insider buying ($527k). Main risk to monitor: Possible yield trap.

Outperform prob.
53%
vs S&P 500 · 12M
medium confidence
Expected return
-3.7% → +20.3%
mid +8.3% / yr
Downside (p20)
-7.7%
stress -15.3%
Data quality
98/100
Excellent
Prism Score

Probabilistic research output, not financial advice. Prism recommendations are based on available data, historical relationships, and model assumptions. They do not guarantee future returns. Conduct independent due diligence before any investment decision.

Backtested and similar-setup statistics may be affected by survivorship bias, look-ahead bias, overfitting, transaction costs, liquidity constraints, and data limitations. Probability estimates are anchored heuristics — not validated forecasts — until the walk-forward backtest pipeline is in place.

Prism Score

Composite 65/100. Strongest contribution from quality; weakest from valuation. Risk patterns shaved 4 points off the composite.

Composite
65
/ 100
Attractive
Deep valueval.
90/ 100

P/B 1.71× · FCF yield 8.3%

Margin of safetyval.
28/ 100

32% above fair value

Bull · base · bear scenarios

Three plausible paths over a 5-year horizon.

Indicative only. Probabilities are model-implied weights for stress-testing — not forecasts.

Bull
~20%
$25.69
-0.3% / yr (5y)

A turnaround takes hold: margin recovers toward peer averages, revenue stabilises, and the market re-prices the asset value rather than the running earnings.

Drivers
  • • Margin expands by 200–400 bps from 32%
  • • Stranded asset value crystallises
  • • Multiple re-rates one full turn higher
Base
~45%
$19.76
-5.4% / yr (5y)

No deterioration, no surprise re-acceleration. 32% operating margin and 5% top-line growth chug along; the multiple slowly converges to the central fair-value estimate.

Global value comparison

Pfizer Inc. vs sector medians — GCC, MENA, and Global ex-US.

Sector: Healthcare. MENA-aware investors can sanity-check whether the US name is offering value relative to regional peers.

MetricPFEGCC medianMENA medianGlobal ex-US
P/E (TTM)—24.0×—20.0×
P/B1.71×4.80×—3.80×
Dividend yield6.66%1.40%—1.80%
ROE8.3%
Earnings reaction explainer

PFE beat by 9.8%.

Beat· +9.8%

Reported EPS $0.75 vs $0.68 expected — a routine beat. Read the rest of the print (guidance, margins, segment mix) before assuming the multiple should expand. Trailing operating margin: 31.6%.

  • Quality investorsPositive

    A routine beat with stable margins is the textbook compounder pattern — nothing changes in the thesis.

  • Value investorsNeutral

    Whether the beat matters depends on entry multiple. P/E — sets the bar.

  • Growth investorsNeutral

    Positive but unremarkable — guidance and KPI commentary will move the stock more than the beat itself.

What to watch on the next print

News & events

Next earnings

Wed, Jul 29 · consensus EPS $0.68 · last actual $0.75

  • We Think Pfizer's (NYSE:PFE) Healthy Earnings Might Be Conservative

    Simply Wall St. · just now

  • Prediction: Pfizer Will Beat the Market Over the Next 5 Years

    Motley Fool · just now

  • Arvinas, Pfizer Partner With Rigel Pharmaceuticals on Global VEPPANU Commercialization

    MT Newswires · just now

Key Metrics at a Glance

P/E Ratio (TTM)

N/A

PEG Ratio

13.77

P/B Ratio

1.71

EPS Growth

-10.1%

Revenue Growth

5.4%

Debt / Equity

0.72

Net Cash / Share

$-9.06

Return on Equity

8.3%

Gross Margin

74.8%

Operating Margin

31.6%

FCF / Share

$2.17

Current Ratio

1.25

· Lynch GARP
0/100

PEG < 1 (growth at a discount) is 13.77× — fails "< 1.00×".

  • Walter Schloss· Schloss Deep Value0/100

    P/B < 1.0 (below book) is 1.71× — fails "< 1.00×".

  • Philip Fisher· Fisher Growth13/100

    Revenue Growth > 15% is 5.4% — fails "> 15.0%".

  • See the full rule-by-rule drill-down below
    65/100
    Medium agreement
    Signal families · 1 of 6 signal families positive
    Agreement: Medium
    • Valuationneutral

      Trades meaningfully above the fair-value range — limited margin of safety.

      32% above fair valueReverse DCF: low expectations bar8.3% FCF yield
      41
      /100
    • Qualityneutral

      Quality is mixed — some strengths, some softness.

      Op margin 32%Gross 75%EPS shrinking -10%
      54
      /100
    • Balance sheetneutral

      Capital structure is unremarkable — neither a stress nor a tailwind.

      50
      /100
    • Momentumneutral

      Price trend is unremarkable — neither tailwind nor headwind.

      50
      /100
    • Behaviouralpositive

      Insiders and / or superinvestors are accumulating — informed-money tailwind.

      Insider buying ($527k)1 tracked holders · peak 21.3%
      62
      /100
    • Catalysts & eventsneutral

      Mixed catalyst picture.

      EPS beat (+10%)2 medium-severity flags
      43
      /100
    Positive drivers
    • • Insider buying ($527k)
    • • 1 tracked holders · peak 21.3%
    Key risks
    • • Possible yield trap
    • • Operating leverage appears to have reversed
    Suggested diligence questions
    • 1. Is insider buying coming from operators with informed perspective on near-term results?
    • 2. Quarterly FCF coverage
    • 3. Operating-margin trend
    Similar historical setups[MOCK DATA]

    Among 101 historical setups with similar Prism Score and signal-agreement profiles, 54% beat the benchmark over the next 12 months, with average excess return of +2.1% / yr.

    Probabilistic research output — not financial advice.
    View full thesis
    Quality20%
    78/ 100

    ROE 8% · Op margin 32%

    Balance sheet15%
    71/ 100

    D/E 0.72 · CR 1.25

    Insider convictionown.
    58/ 100

    2 insiders buying

    Superinvestorown.
    79/ 100

    1 tracked holder · peak 21.3%

    Shareholder yield10%
    100/ 100

    6.66% yield + buyback runway

    Momentum5%
    68/ 100

    60% through 52w range

    Growth5%
    34/ 100

    EPS -10% · Rev 5%

    Risk deduction: 2 patterns flagged · possible yield trap. 4 points removed from composite.

    Designed to surface potentially attractive characteristics — descriptive, not prescriptive. For research and educational purposes only.

    Customise weights
    Drivers
    • • Revenue growth holds near 5%
    • • Operating margin stays around 32%
    • • No major balance-sheet surprises
    Bear
    ~35%
    $14.82
    -10.7% / yr (5y)

    Cyclical earnings prove to be at peak; revenue stalls and the multiple, already low, drifts lower as estimates re-rate down.

    Drivers
    • • Operating margin compresses 200–400 bps
    • • Multiple compresses as estimates roll back
    • • Sentiment de-rates the name to a deeper-value multiple
    Indicative weights
    16.0%
    —
    15.0%

    Editorial dataset · as of 2024-12-31. Sector medians are hand-maintained from public Tadawul / ADX / DFM / QSE / EGX disclosures and indicative Global ex-US references. Live licensed data is on the roadmap. For research and educational purposes only.

    • • Whether margin expansion sustains into next quarter
    • • Forward guidance update — beats without raises tend to fade
    • • Dividend coverage commentary
  • Is Pfizer a Buy, Sell, or Hold in 2026?

    Motley Fool · just now

  • Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

    GlobeNewswire · just now

  • This 1 Insane Nvidia Stat Explains Why Wall Street Can’t Stop Buying the Stock

    24/7 Wall St. · just now

  • Institutional Own.

    68.7%

    Insider Own.

    0.1%

    Dividend Yield

    6.66%

    Book Value / Share

    $15.21

    Superinvestor ownership

    Held by 1 tracked superinvestor · peak weight 5.6%

    Grand Portfolio
    • Michael Burry

      Scion Asset Management · Q4 2025

      5.6%

    Weights reflect each investor's latest 13F or factsheet snapshot. Data lags real time by 45+ days.